This inventor holds 3 USPTO granted patents. Top assignee: Mead Johnson & Company. Active years: 1982-1986.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1982-1986
Title: Richard E. Gammans: Innovator and Inventor in Evansville, IN
Introduction: Richard E. Gammans is a notable inventor based in Evansville, Indiana, recognized for his contributions to the field of pharmacology. With three patents to his name, he has a proven track record of innovation, particularly in the development of pharmaceutical compounds aimed at improving patient health.
Latest Patents: Among his latest patents, Richard has developed a benzamide compound, specifically the 4-Hydroxy-3-methoxy-N-[2-[2-(1-methyl-2-piperidinyl)ethyl]-phenyl]benzamide, which serves as an antiarrhythmic agent. This compound is distinguished by its relatively low toxicity and increased duration of action, making it a promising candidate for clinical use. Additionally, he has worked on antidepressant 1,2,4-triazolone compounds, including 2-[3-[4-(3-Halophenyl)-1-piperazinyl]propyl]-5-(1-hydroxyethyl)-2,4-dihydro -[4-phenoxyalkyl-3H-1,2,4-triazol-3-ones. These compounds exhibit psychotropic properties with significant potential as antidepressants, attributed to their favorable receptor site binding affinity profiles and supporting animal pharmacology.
Career Highlights: Richard is currently employed at Mead Johnson & Company, where he applies his expertise in pharmacological research and development. His dedication to innovation and patient care is evident in his work, contributing to advancements that impact the healthcare industry positively.
Collaborations: Throughout his career, Richard has collaborated with several talented individuals, including colleagues Robert F. Mayol and David W. Smith. These collaborative efforts enhance the scope of research and innovation within their projects, leading to the development of valuable therapeutic agents.
Conclusion: Richard E. Gammans exemplifies the spirit of innovation within the pharmaceutical industry. His work on patents related to antiarrhythmic and antidepressant agents showcases his commitment to improving medical treatments. As he continues his journey at Mead Johnson & Company, his contributions are sure to influence the future of healthcare positively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile